Want to see MNPR full AI Analyst Report?
MNPR Stock Chart & Stats
$56.22
-$0.61(-2.42%)
At close: 4:00 PM EST
$56.22
-$0.61(-2.42%)
Day’s Range― - ―
52-Week Range$29.18 - $105.00
Previous CloseN/A
Volume23.12K
Average Volume (3M)166.73K
Market Cap
$451.99M
Enterprise Value$378.94M
Total Cash (Recent Filing)$137.49M
Total Debt (Recent Filing)$131.56K
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 06, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.07
Shares Outstanding6,699,062
10 Day Avg. Volume123,716
30 Day Avg. Volume166,732
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)3.51
Price to Sales (P/S)0.00
P/FCF Ratio-39.66
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-24.23
Forecast
1Y Price Target
$113.33Price Target Upside101.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Efficacy (ALXN1840 Phase 3)Durable Phase 3 efficacy across neurologic endpoints and sustained benefit over roughly three years materially strengthens the clinical profile. This reduces development risk, supports regulatory filings and future clinician adoption, and underpins a differentiated market position in Wilson disease.
Favorable Safety Across StudiesA consistent safety record across substantial patient-years lowers regulatory and commercial risk. Favorable tolerability supports broader label potential, eases post-approval monitoring burdens, and increases partner and prescriber confidence—key durable advantages for rare-disease uptake.
Low Financial LeverageMinimal debt reduces fixed financing obligations and bankruptcy risk, preserving optionality for strategic choices. For a development-stage biotech this durable balance-sheet strength improves flexibility to time financings or partnerships without servicing heavy interest costs as clinical programs progress.
Bears Say
Pre-revenue With Escalating LossesOperating without product revenue and widening net losses is a structural constraint: the company must rely on external funding to continue development. Persistent losses increase dilution risk and pressure management to demonstrate near-term clinical or partnership milestones to secure long-term financing.
Consistent Negative Cash Flow / Worsening BurnSustained negative operating and free cash flow indicates runway compression and a higher probability of financing needs. This elevates execution risk for multi-year clinical programs, can delay plans if capital is scarce, and may force non-strategic financing decisions that affect shareholders.
Business Model Reliant On Capital RaisesDependence on equity or financing transactions for funding is a structural vulnerability. Future program continuity and commercialization depend on successful capital access or partnerships; failure or unfavorable terms would dilute shareholders and could slow development or commercialization timelines.
Monopar Therapeutics Inc News
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $29.18 and its highest was $105.00 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is $451.99M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 30 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on May 14, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.721 by $0.261.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate is -0.66.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,699,062 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.721. Following the earnings report the stock price went down -0.732%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monopar Therapeutics Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$113.33 (101.59% Upside)
$113.33 (101.59% Upside)
Blogger Sentiment
Bullish
MNPR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 152.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.6%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
178.12%
12-Months-Change
Fundamentals
Return on Equity
-12.84%
Trailing 12-Months
Asset Growth
150.49%
Trailing 12-Months
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
MNPR Stock 12 Month Forecast
Average Price Target
$113.33
▲(101.59% Upside)
Technical Analysis
Cardiff Oncology
―
Vanda
―
Verastem
―
Mereo Biopharma Group Plc
―
Silence Therapeutics
―
Ownership Overview
18.14% Insiders
6.76% Mutual Funds
45.93% Other Institutional Investors
22.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---